Lomustine and Bevacizumab in Progressive Glioblastoma
Lomustine and Bevacizumab in Progressive Glioblastoma
About this item
Full title
Author / Creator
Wick, Wolfgang , Gorlia, Thierry , Bendszus, Martin , Taphoorn, Martin , Sahm, Felix , Harting, Inga , Brandes, Alba A , Taal, Walter , Domont, Julien , Idbaih, Ahmed , Campone, Mario , Clement, Paul M , Stupp, Roger , Fabbro, Michel , Le Rhun, Emilie , Dubois, Francois , Weller, Michael , von Deimling, Andreas , Golfinopoulos, Vassilis , Bromberg, Jacoline C , Platten, Michael , Klein, Martin and van den Bent, Martin J
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival...
Alternative Titles
Full title
Lomustine and Bevacizumab in Progressive Glioblastoma
Authors, Artists and Contributors
Author / Creator
Gorlia, Thierry
Bendszus, Martin
Taphoorn, Martin
Sahm, Felix
Harting, Inga
Brandes, Alba A
Taal, Walter
Domont, Julien
Idbaih, Ahmed
Campone, Mario
Clement, Paul M
Stupp, Roger
Fabbro, Michel
Le Rhun, Emilie
Dubois, Francois
Weller, Michael
von Deimling, Andreas
Golfinopoulos, Vassilis
Bromberg, Jacoline C
Platten, Michael
Klein, Martin
van den Bent, Martin J
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_inserm_02940442v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_inserm_02940442v1
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1707358
